Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You have been diagnosed with an advanced, spread, or returning cancer (mainly colorectal, esophageal, stomach, or pancreatic cancer) confirmed by a tissue or lab test
- Your cancer has continued to grow or you could not tolerate at least two rounds of standard treatments (such as surgery, chemotherapy, or radiation), or there are no effective treatments left for you
- A recent tumor tissue test (within the last 3 months) showed a protein called CEA on at least 10% of tumor cells, and if only certain types of tumors are involved, your blood CEA level must also be above 10 µg/L (confirm with trial site)
- You have at least one tumor that can be measured by scan, meeting specific size requirements
- You are reasonably active and able to care for yourself, based on a standard performance scale (ECOG score 0–2) (confirm with trial site)
- You do not have a serious mental health condition
- Your blood counts, heart, kidneys, liver, and oxygen levels meet certain minimum health standards (confirm with trial site for exact values)
- You are able to have blood collected through a standard procedure
- You agree to use reliable contraception for one year after receiving the trial treatment (methods based on tracking your cycle are not considered reliable for this purpose)
- You or your legal guardian agree to take part and sign a consent form after understanding the trial's purpose and procedures
Who may not be able to join:
- Your cancer has spread to your brain or the lining around your brain and the study doctor thinks this makes you unsuitable
- You have taken part in another clinical trial within the last month
- You received a live vaccine (such as certain flu or travel vaccines) within the past 4 weeks
- You received chemotherapy, targeted therapy, or other experimental cancer drugs within the past 14 days or within a recent short window based on how quickly those drugs leave your body
- You currently have an active or uncontrolled infection that requires treatment
- You have a bowel blockage, active bleeding in your digestive tract, or had digestive bleeding in the past 3 months
- You have a large amount of uncontrolled fluid build-up in body cavities (such as around the lungs or abdomen)
- You still have significant side effects from previous cancer treatment (other than hair loss or mild nerve tingling) that have not returned to near-normal levels
- You have certain serious heart conditions, including severe heart failure, a heart attack or heart bypass surgery in the past 6 months, significant irregular heart rhythms, unexplained fainting, or a history of severe non-ischemic heart muscle disease
- You have an active autoimmune disease or need long-term medication to suppress your immune system
- You have had or currently have another unrelated cancer in the past 3 years (except certain early-stage skin or cervical cancers)
- You have active or uncontrolled Hepatitis B, Hepatitis C, HIV, or syphilis based on blood tests
- You are currently pregnant or breastfeeding
- The study doctor decides for any other reason that joining would not be appropriate for you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: lili Sheng, M.D, First Affiliated Hospital of Wannan Medical College
Phone: 13605535185
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-associated Adverse Events [Safety and Tolerability]; Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.